The Intervention Effect of Externally Applying or Orally Administering Bifidobacterium Animalis Subsp. Lactis J12 on Atopic Dermatitis Induced by 2,4-Dinitrofluorobenzene
January 2026
in “
Microorganisms
”
Bifidobacterium animalis subsp. lactis J12 atopic dermatitis 2,4-dinitrofluorobenzene gut microbiota systemic immune regulation topical application oral administration inflammatory cytokines regulatory T cells Bifidobacterium lactis J12 AD gut bacteria immune system topical treatment oral treatment inflammation T cells
Studysummary In a DNFB-induced mouse model of atopic dermatitis, this study found that both topical and oral formulations of the probiotic <i>Bifidobacterium animalis</i> J12 improved AD symptoms through distinct mechanisms, with topical applications reducing local inflammation and oral administration enhancing gut microbiota and reducing systemic inflammation. Our plain-language summary of this paper — not a Tressless recommendation.
This study evaluated the effects of Bifidobacterium animalis subsp. lactis J12 on atopic dermatitis (AD) in a mouse model induced by 2,4-dinitrofluorobenzene. Involving 108 mice, the study compared oral and topical applications of J12, finding both methods significantly alleviated AD symptoms. Oral administration improved gut microbiota and systemic immune regulation, while topical application provided local anti-inflammatory benefits. Both approaches reduced inflammatory cytokines and increased regulatory T cells, suggesting J12's potential as a therapeutic option for AD through distinct mechanisms.
